Drugs / mRNA-1273.214
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05585632 | Oct 2022 → Feb 2024 | Orthocoronavirinae infectious disease, influenza, respiratory syncytial virus infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05584202 | Sep 2022 → Nov 2024 | COVID-19 | ModernaTX, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05383560 | Sep 2022 → Jan 2024 | COVID-19 | Sheba Medical Center | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05249829 | Feb 2022 → Jun 2023 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT04927065 | May 2021 → Nov 2023 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT04796896 | Mar 2021 → Mar 2024 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05436834 | Jun 2022 → Oct 2025 | COVID-19 | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05330975 | Apr 2022 → Nov 2024 | respiratory syncytial virus infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT05658523 Comparator | Feb 2023 → Oct 2024 overdue | COVID-19 | Murdoch Childrens Research Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05543356 Comparator | May → Jul 2022 | COVID-19 | Murdoch Childrens Research Institute | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05471440 Comparator | Aug → Sep 2022 | — | Erasmus Medical Center | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1273.214 | “Biological/Vaccine: Moderna, mRNA-1273.214 - bivalent The Moderna bivalent vaccine (mRNA-1273.214) encodes the prefusion stabilized S protein of SARS-CoV-2 formulated in...” NCT05543356 ↗9“The BNT162b2 OMI BA.1 boost was given to participants younger than 45 years, and the mRNA-1273.214 boost was given to participants 45 years or older, as per Dutch guidelines.” PMID 37088096 ↗ Apr 2023 |
| Known as | Bivalent Moderna | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05543356 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-1273.214 (25 μg; omicron BA.1 and ancestral Wuhan-Hu-1 mRNA) primary series” PMID 38518789 ↗ Mar 2024 |
| Route | Intramuscular | “1 IM injection as Dose 3” NCT04796896 ↗ |